In a regulatory filing, Viridian Therapeutics disclosed that its CEO Stephen Mahoney bought 21.4K shares of common stock on September 27th in a total transaction size of $499.3M. Viridian Therapeutics shares ended after-hours session up 4% at $23.63.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics price target raised to $61 from $56 at BTIG
- Largest borrow rate increases among liquid names
- Viridian Therapeutics price target raised to $44 from $35 at RBC Capital
- Viridian Therapeutics 10.67M share Secondary priced at $18.75
- Closing Bell Movers: Dave & Busters jumps 10% after earnings beat